Innovent Biologics Inc, a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative medicines, has announced a new strategic collaboration with Eli Lilly and Company to advance novel therapies in oncology and immunology. This agreement represents the seventh partnership between Innovent and Lilly and further strengthens a relationship that has evolved over more than a decade. The collaboration reflects a shared commitment to bringing innovative treatments to patients worldwide and introduces a new framework designed to speed the global progress of Innovent’s growing research pipeline.
Health Technology Insights: Lōkahi Therapeutics Welcomes UGA Fellows to ai² Futures Lab
Through this collaboration, both companies will combine their respective strengths to accelerate the development of new medicines on a global scale. Innovent will take primary responsibility for advancing selected programs in China, guiding them from early discovery through Phase 2 clinical proof of concept. This work will be supported by Innovent’s antibody technology platforms and its track record of efficient clinical execution. Lilly will receive exclusive rights to further develop and commercialize these programs outside Greater China, while Innovent will maintain development and commercialization rights within Greater China.
Health Technology Insights: Ambience Healthcare Teams With MultiCare on AI Platform Rollout
Dr Michael Yu, Founder, Chairman of the Board, and Chief Executive Officer of Innovent, said the collaboration builds on a trusted partnership that has lasted more than ten years. He explained that working with Lilly allows Innovent to pair its strengths in discovery and early clinical development with Lilly’s global development and commercialization capabilities. According to Yu, the collaboration goes beyond a traditional licensing arrangement and establishes a more integrated innovation model that supports faster translation of scientific research into meaningful therapies for patients with cancer and immune related diseases. He added that the partnership underscores Innovent’s growing research capabilities and its ambition to deliver high quality medicines to patients around the world.
As part of the agreement, Innovent will receive an upfront payment of 350 million dollars. The company is also eligible for additional development, regulatory, and commercial milestone payments that could total up to approximately 8.5 billion dollars, depending on the achievement of specific future milestones. In addition, Innovent may receive tiered royalties based on net sales of each product commercialized outside Greater China.
The collaboration highlights both companies’ focus on global innovation and their shared goal of expanding treatment options in oncology and immunology through efficient cross border development and long term strategic alignment.
Health Technology Insights: Oncotype DX Breast Test Exceeds 2 Million Patients Globally
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
